Have an account? Log in.
I don't have an account.
https://news.bloomberglaw.com/privacy-and-data-security/merck-to-settle-bulk-of-gardasil-lawsuits-for-around-50-million
Moderna reports five-year melanoma trial results with Merck and expands its Ebola vaccine partnership with CEPI, but MRNA stock is down.
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab),
Dell, Qualcomm and HP power an AI-fueled rally to send the Dow to record highs. Nasdaq 100 and S&P 500 eyes eighth straight week of gains.
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending
A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commission (FTC) and the Food
STELLAR-316 is a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer (CRC). Under the terms of the clinical development collaboration with Merck, Exelixis is sponsoring the STELLAR-316
https://www.cdc.gov/ebola/situation-summary/index.html
Sac-TMT is the first TROP2 ADC to improve OS and PFS compared to chemotherapy in patients with advanced or recurrent endometrial cancer who have progressed after platinum-based chemotherapy and anti-PD-1/L1 immunotherapy